Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Woori Bio Co., Ltd. (082850:KRX), powered by AI.
Woori Bio Co., Ltd. is currently trading at ₩1,403. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Woori Bio Co., Ltd. on Alpha Lenz.
Woori Bio Co., Ltd.'s P/E ratio is -7.3.
“Woori Bio Co., Ltd. trades at a P/E of -7.3 (undervalued) with modest ROE of -4.5%.”
Ask for details →Woori Bio Co., Ltd. is a notable player in the biotechnology sector, primarily focused on the development, manufacturing, and marketing of advanced healthcare solutions. The company specializes in creating cutting-edge bio-products and services designed to enhance human health and well-being. With a strong emphasis on research and innovation, Woori Bio is involved in various areas of biotechnology, including pharmaceuticals, biochemistry, and regenerative medicine. Woori Bio Co., Ltd. plays an integral role in advancing medical technology, impacting sectors such as pharmaceuticals, healthcare, and possibly agriculture, by contributing to the development of biosimilar drugs and other medical solutions. The company's efforts in biotechnology hold substantial significance, particularly in developing novel treatments and therapies, which are crucial in addressing a wide range of medical conditions and enhancing the quality of life. As the biotechnology industry continues to evolve, Woori Bio Co., Ltd. remains a key contributor by leveraging its expertise in scientific research and development, underscoring its importance to the global biotech landscape and the ongoing advancement of medical sciences.
“Woori Bio Co., Ltd. trades at a P/E of -7.3 (undervalued) with modest ROE of -4.5%.”
Ask for details →Woori Bio Co., Ltd. (ticker: 082850) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $68.0B.
The current price is ₩1,403 with a P/E ratio of -7.25x and P/B of 0.33x.
ROE is -4.50% and operating margin is 0.09%. Annual revenue is $1.0T.